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We have been investigating the molecular eﬃcacy of electroacupuncture (EA), which is one type of acupuncture therapy. In our
previous molecular biological study of acupuncture, we found an EA-induced gene, named acupuncture-induced 1-L (Aig1l), in
mouse skeletal muscle. The aims of this study consisted of identiﬁcation of the full-length cDNA sequence of Aig1l including the
transcriptional start site, determination of the tissue distribution of Aig1l and analysis of the eﬀect of EA on Aig1l gene expression.
We determined the complete cDNA sequence including the transcriptional start site via cDNA cloning with the cap site hunting
method.WethenanalyzedthetissuedistributionofAig1l bymeansofnorthernblotanalysisandreal-timequantitativepolymerase
chain reaction. We used the semiquantitative reverse transcriptase-polymerase chain reaction to examine the eﬀect of EA on Aig1l
geneexpression.OurresultsshowedthatthecompletecDNAsequenceofAig1l was6073bplong,andtheputativeproteinconsisted
of 962 amino acids. All seven tissues that we analyzed expressed the Aig1l gene. In skeletal muscle, EA induced expression of the
Aig1l gene, with high expression observed after 3 hours of EA. Our ﬁndings thus suggest that the Aig1l gene may play a key role in
the molecular mechanisms of EA eﬃcacy.
1.Introduction
Traditional Eastern medicine, such as acupuncture, moxi-
bustion and Chinese herbal medicine, originated in ancient
China and has developed unique forms in East Asian
countries (mainly Japan, China and Korea). These practices
are called traditional Japanese medicine (Kampo), Chi-
nese medicine and traditional Korean medicine [1]. Elec-
troacupuncture(EA)isawell-knownacupuncturetechnique
used in East Asia. EA utilizes stimulation of acupuncture
needles with a low-frequency microcurrent [2].
Comprehensive analysis of changes in gene expression
is called transcriptome analysis, which has provided a
number of ﬁndings to medical science. cDNA microarray
and GeneChip array methods allow such comprehensive
gene expression analysis [3, 4]. Certain research groups
havereportedinvestigations ofgeneexpressioninEA-treated
animals in which they used cDNA microarrays. Kim et al.
[5] reported that 30 minutes of EA applied every 16 hours
for 2 days induced a change in expression of genes related to
natural killer cell activity in the spleen. Ko et al. [6] showed
that gene expression of mitogen-activated protein kinase II
(MAPK II), Fas-AP and LIM increased in spinal cord after 3
weeks of daily application of EA for 30 minutes. Chae et al.
[7] reported research on acupuncture-treated humans that
they analyzed by using a cDNA microarray; after correlating2 Evidence-Based Complementary and Alternative Medicine
gene expression with responses to acupuncture stimulation,
they found individual diﬀerences in acupuncture analgesia.
We have also analyzed the eﬀect of EA at the gene
transcriptional level [2]. In that study, we found that EA
stimulation caused myostatin gene suppression leading to
satellite cell proliferation in skeletal muscle. During that
study, we discovered a previously unknown gene that was
induced by EA in mouse skeletal muscle and named it Aig1l.
We found high expression of this gene after EA stimulation
in mouse skeletal muscle. This ﬁnding agrees with clinical
observations that the eﬀect of acupuncture appears some
time after stimulation, and it led us to further analysis of this
gene.
In the study described here, we used cDNA cloning
with the cap site hunting method [8] to determine the full-
length cDNA sequence of Aig1l, the full-length sequence
consisting of the transcriptional start site to the poly(A)
tail. Complete full-length cDNA sequencing is important for
functional analysis of the gene; knowing the transcriptional
start site makes it possible to evaluate the transcriptional
regulatory domain by bioinformatics analyses. Indeed, we
used bioinformatics to analyze the transcriptional regulatory
domain of Aig1l. We also analyzed the full-length cDNA
sequence by bioinformatics analysis and detected functional
domains of Aig1l. Finally, we examined Aig1l expression in
each tissue by using northern blot analysis and real-time
quantitative polymerase chain reaction (real-time PCR). For
the relation between the Aig1l gene and EA, we investigated
Aig1l expression via semiquantitative reverse transcriptase
polymerase chain reaction (RT-PCR) at diﬀerent times after
EA stimulation of muscle.
2. Methods
2.1. Animals and EA Conditions. Inbred C57BL/6 male mice,
8 weeks old, were purchased from Charles River Laboratories
(Yokohama, Japan). For EA stimulation, we used stainless-
steel acupuncture needles (40mm long and 0.16mm in
diameter; Seirin, Shizuoka, Japan). We inserted the needles
into ﬁve anesthetized mice to a depth of 5–7mm and
then stimulated the needles with an electrical stimulator
(Kyushu Ryoudoraku, Fukuoka, Japan). Hindleg muscles of
mice received EA stimulation at points corresponding to
the acupoints BL36 and BL59 (for details, see our web site:
http://bionano.med.kobe-u.ac.jp/adss/)f o r1 5m i n u t e sw i t h
1.2Hz repetitions, according to our previous study [2]. We
similarly anesthetized a control group of ﬁve mice but did
not treat them with EA.
This research was performed according to the Standards
Relating to the Care and Management, and so forth. of
Experimental Animals (Ministry of the Environment, Tokyo,
Japan) [9]. This study was approved by the Committee
for Safe Handling of Living Modiﬁed Organisms of Kobe
University (Permission number 17–21) and was carried out
according to the guidelines of the Committee.
2.2. RNA Extraction and cDNA Synthesis. We extracted total
RNAfromvarioustissues(brain,skeletalmuscle,heart,lung,
spleen,liverandkidney)obtainedfromnon-EA-treatedmice
by using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
method.
To extract total RNA, we prepared skeletal muscles
(gastrocnemius, soleus, biceps femoris and gluteus) from
EA-treated mice at the time points of immediately after EA
(0 hours) and then 1, 3 and 24 hours after EA (n = 5
for each time point). We chose these time points on the
basis of our clinical experience and observations during
acupuncture treatment, which we classiﬁed into two groups:
“rapid eﬀect” for immediately (0 hours) and 1 and 3 hours
after EA, and “late eﬀect” for 24 hours after EA. We similarly
extracted total RNA from skeletal muscles from the control
group. For each PCR analysis, we reverse transcribed total
RNA (5μg) into cDNA by using the SuperScript First-Strand
Synthesis System for RT-PCR (Invitrogen), according to the
manufacturer’s instructions.
2.3. Northern Blot Analysis. We subjected the denaturated
total RNA (1μg) to electrophoresis on 1.2% agarose/2%
formaldehyde gel and then transferred the samples to
a positively charged nylon membrane. To generate anti-
sense RNA probes, we cloned a 509bp of Aig1l cDNA
fragment (nucleotide positions 3720–4228) derived from
the PCR ampliﬁcation by using the TOPO TA cloning kit
(Invitrogen). We prepared digoxigenin-labeled RNA probes
with DIG RNA Labeling Mix (Roche Diagnostics GmbH,
Mannheim, Germany). The membrane was hybridized with
DIG-labeled RNA probes just described in DIG Easy Hyb
(Roche Diagnostics) at 68◦C overnight. Then, excess probe
was washed away: 2× SSC/0.1% SDS was used twice at
RT, and then 0.1× SSC/0.1% SDS was used twice at 68◦C.
Hybridized DIG-labeled RNA was detected by means of
alkaline phosphatase-conjugated anti-DIG antibody (Roche
Diagnostics), after which CSPD Substrate was added and the
membrane was exposed to X-ray ﬁlms to obtain signals. The
membrane was rehybridized with the DIG-labeled mouse
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) RNA
probe (Genostaﬀ, Tokyo, Japan) as an internal control.
2.4. Real-Time Quantitative PCR and Semiquantitative RT-
PCR. Real-time quantitative PCR was performed by using
SYBR Green I and a LightCycler (Roche Diagnostics),
according to the manufacturer’s instructions. The reaction
mixture consisted of 2μl of FastStart DNA Master SYBR
GreenI(RocheDiagnostics),2mMMgCl2,2μlofcDN Aand
each primer at 10 pmol, plus water to a ﬁnal volume of 20μl.
The PCR conditions were 95◦C for 10 minutes followed by
40 cycles in three steps: 95◦C for 15s, 58◦C for 10s and 72◦C
for 25s and then 60◦C for 10s. The primers used for real-
timePCRwereasfollows:forAig1l,sense:5  -TTGAAGCCA-
GCTCTTTGGAG-3  and antisense: 5 -TTTGCCTACGGT-
TCCTGAAG-3 ; for G3PDH, which served as an internal
control [10], sense: 5 -GGAAAGCTGTGGCGTGATG-3 
and antisense: 5 -CTGTTGCTGTAGCCGTATTC-3 .
For semiquantitative RT-PCR, for which we used a ther-
malcycler(GeneAmpPCRSystem9700;AppliedBiosystems,











Figure 1: PCR primer sets for the cap site hunting method analysis of the Aig1l gene. The cap site hunting method allowed detection of the
transcriptional start site of the gene. Horizontal arrows indicate positions of the primer pairs. In the ﬁrst PCR, we prepared primer sets for
the brain (RDT1 and R4) and skeletal muscle (RDT1 and R3). In the nested PCR, we prepared primer sets for the brain (RDT2 and R2) and
skeletal muscle (RDT2 and R1). The vertical arrow points to the transcriptional start site. Underlining shows the start codon atg. Italic letters
designate the synthetic rOligo sequence ligated to the mRNA.
5 pmol primers, 0.4 unit AmpliTaq Gold DNA polymerase
(Perkin-Elmer/Cetus, Tokyo, Japan), 1× PCR buﬀer and
200μl/l dNTPs. We analyzed the Aig1l gene expression pat-
tern after the EA stimuli by means of RT-PCR with primers
as follows: sense: 5 -ACTGGGATACACTCGTGAGC-3 ;
antisense: 5 -GACACAGGAAGGTCACCACCA-3 .P r i m e r s
of G3PDH for RT-PCR were the same as the ones used for
real-time PCR. We then performed 28 cycles of ampliﬁcation
(one cycle: denaturation at 94◦C for 60s, annealing at 55◦C
for 60s and extension at 72◦C for 60s), and we analyzed
449bp PCR products from Aig1l by using 1.5% agarose
gel electrophoresis. After electrophoresis, we determined
the densitometric values of these PCR bands by the same
procedure that we reported in our previous study [2], using
the ImageJ program (Wayne Rasband, National Institutes of
Health, Bethesda, MD, USA).
2.5. Full-Length cDNA Sequencing and Bioinformatics Anal-
ysis. We ampliﬁed a partial sequence of Aig1l by use of
twoprimers—forward,5 -ACTGGGATACACTCGTGAGC-
3 ,andr ev erse,5  -GACACAGGAAGGTCACCACCA-3 —as
probes. The Aig1l p r o b es e r v e dt os c r e e nt h em o u s eb r a i n
cDNA library (Stratagene, La Jolla, CA, USA). We screened
with the labeled probe by means of the AlkPhos Direct
system (Amersham Biosciences Corp., Piscataway, NJ, USA),
according to the manufacturer’s protocol. We isolated and
puriﬁedpositiveclones.WethenperformedautomatedDNA
sequencing analysis by using the ABI Prism 377 with the
BigDye Terminator Cycle Sequencing Reaction Kit (Applied
Biosystems). We conﬁrmed sequencing results with both
strands.
We determined the transcriptional start site of the
Aig1l gene by using the cap site hunting method with
mouse skeletal muscle and brain cap site cDNA (Nippon
Gene, Toyama, Japan), according to the manufacturer’s
instructions. The procedure for synthesis of cap site cDNA
was reported previously [8] as follows: we removed the cap
s t r u c t u r eo fm R N Aw i t ht o b a c c oa c i dp y r o p h o s p h a t a s e .W e
then ligated a synthetic oligoribonucleotide to the decapped
mRNAswithT4RNAligase.WeconvertedtheligatedmRNA
to cDNA by using reverse transcriptase, with oligo(dT) as a
primer. In this study, we ﬁrst performed PCR with the cap
site cDNA and then performed nested PCR. Figure 1 shows
the primer sets for those PCRs. We ampliﬁed samples of
the ﬁrst PCR for 35 cycles under the following conditions:
denaturation for 20s at 95◦C, annealing for 20s at 60◦C
and extension for 90s at 72◦C. We used aliquots of the ﬁrst
PCR reaction as the template in the nested PCR reaction,
performed under the same conditions. We then excised PCR
products from the low-melting-temperature 1.5% agarose
gel, inserted them into the TA vector, and sequenced them.
After we sequenced the full-length cDNA, we performed
bioinformatics analysis of Aig1l by using the Pfam database
(http://pfam.sanger.ac.uk/). Then, to analyze the transcrip-
tional control regions of Aig1l genes (upstream from the
ascertained transcriptional starting point), we used SHAFT
(https://suzume.med.kobe-u.ac.jp/SHAFT/), an automated
application of the search and choice analyses for transcrip-
tion factors that we previously developed [2].
3. Results
3.1. Cloning of the Full-Length cDNA Sequence of Aig1l and
Bioinformatics Analysis of the Gene. We determined the full-
length cDNA sequence of the Aig1l gene via cDNA cloning
and use of the mouse brain cDNA library, because the
brain showed high expression of the gene. We ascertained
the transcriptional starting point of the gene by means of
the cap site hunting method with cap site cDNAs from
mouse brain and from mouse skeletal muscle, because the
transcriptional start site is not included in the usual cDNA
libraries. We obtained the same transcriptional start site
from cap site cDNA of both mouse brain and muscle. After
we determined the complete cDNA sequence of Aig1l,w e
registered it with the GenBank genome database (GenBank
accession no. DQ167195). The full-length cDNA sequence
was 6073bp long, and the putative protein consisted of 962
amino acids (Figure 2). Bioinformatics analysis performed
via the Pfam database indicated that Aig1l includes CUB and
Sushi domains. The transcriptional control region, near the
transcriptional start site, of the Aig1l gene has Sp1, CP2 and
MZF1 binding motifs that we detected by using the SHAFT
program.4 Evidence-Based Complementary and Alternative Medicine
Figure 2: Nucleotide and deduced amino acid sequences of the Aig1l gene. The lowercase upper letters correspond to the nucleotide
sequence. The capital letters refer to the deduced amino acid sequence. The numbers at the ends of the lines indicate nucleotide positions.
Underlining shows the initiation codon atg. The closed boxes with white letters designate the CUB domain; the open boxes with black letters
indicate the Sushi domain. An asterisk indicates the stop codon (taa). A double underline identiﬁes the poly(A) signal sequence.
3.2. Tissue Distribution of the Aig1l Gene and Characteristics
of Gene Expression Induced by EA. All tissues, brain, skeletal
muscle, spleen, heart, lung, kidney and liver, expressed
the Aig1l gene as determined by semiquantitative RT-PCR:
the highest expression was found in the brain (data not
shown). Northern blot analysis performed in the normal
sensitivity mode showed high Aig1l gene expression in
the brain (Figure 3(a)); the northern blot analysis per-
formed in the high sensitivity mode revealed very weak
gene expression in the heart, lung and spleen (data not
shown). In addition, real-time quantitative PCR analysis also
indicated that the brain had the highest Aig1l gene expres-
sion and all other tissues had very weak gene expression
(Figure 3(b)).
We then analyzed the eﬀect of EA on Aig1l expression
in skeletal muscle by using semiquantitative RT-PCR. EA
induced expression of Aig1l at each time point. We found the





BM HL uS L KN C
(a)
300.0
2.82 .52 0 .81 6 .14 .83 .5 %o fb r a i n
(means±SD) ±1.0 ±0.9 ±4.1 ±6.0 ±4.5 ±1.0
(b)




(c) C0132 4 N C
(c)
Figure 3: Tissue distribution and eﬀect of EA on Aig1l gene
expression. (a) Tissue distribution of Aig1l as detected by northern
blot analysis in the normal sensitivity mode. (b) Tissue distribution
of Aig1l as detected by real-time quantitative PCR analysis (n =
5). (c) Semiquantitative RT-PCR analysis of Aig1l gene expression
in skeletal muscle after EA. Lanes are as follows: C: no EA
stimulation (control); 0: EA-treated sample just after stimulation;
1, 3 and 24: EA-treated samples at 1, 3 and 24 hours after
stimulation, respectively; NC: negative PCR control containing no
cDNA template in the PCR mixture; G3PDH served as a loading
control. The following tissues expressed the Aig1l gene in (a) and
(b): brain, B; muscle, M; heart, H; lung, Lu; spleen, S; liver, L and
kidney, K. NC indicates negative control.
4. Discussion
In this research, we determined the full-length cDNA
sequence of the mouse Aig1l gene, which EA stimulation
induced in mouse skeletal muscle, and analyzed its expres-
sion. Because skeletal muscle expressed the Aig1l gene after
EA stimulation, this gene may be involved in the molecular
mechanism of the eﬀectiveness of EA therapy.
We performed full-length cDNA cloning of the Aig1l
gene, including the transcriptional start site. We determined
this site via the cap site hunting method (Figure 1). The
complete cDNA sequence was 6073bp long and mapped to
chromosome 5 in the mouse genome database. The mouse
Aig1l gene is a homologue of the human SEZ6L gene [11].
The coding sequences of these genes showed 79% homology.
The human SEZ6L gene is a homologue of the mouse Sez6
gene, which research on seizures has detected [12, 13]. The
coding sequences for Aig1l and the mouse Sez6 showed
54.8% homology. This ﬁnding may reﬂect the eﬀect of EA
stimulation on the brain and nervous system in view of the
relation among the gene Aig1l and the seizure-related genes
Sez6 and SEZ6L.
Our investigation of the tissue distribution of Aig1l
gene expression revealed the greatest expression in the
brain, as evidenced by semiquantitative RT-PCR (data not
shown), northern blot analysis (Figure 3(a)) and real-time
quantitative PCR analysis (Figure 3(b)). All other tissues
evaluated—skeletal muscle, heart, lung, spleen, liver and
kidney—had much weaker Aig1l expression than the brain
(Figures 3(a) and 3(b)). The human SEZ6L gene was also
reportedly detected in various tissues [11].
Bioinformatics analysis of Aig1l near the transcriptional
control region showed Sp1, CP2 and MZF1 binding motifs.
Sp1 and CP2 are ubiquitously expressed transcription fac-
tors. Sp1 functions in development and diﬀerentiation [14,
15], and CP2 operates in regulation of erythroid genes [16,
17]. MZF1 is involved in proliferation and diﬀerentiation
[18]. These bioinformatics results agree with ﬁndings on the
tissue distribution of Aig1l gene expression.
Our analysis with the Pfam database showed that Aig1l
has CUB and Sushi domains (Figure 2). CUB domains occur
almost exclusively in extracellular and plasma membrane-
associated proteins, and in proteases [19–21]. Those proteins
reportedlyparticipateinawiderangeofbiologicalfunctions:
developmental processes [22–25], neurotransmission [26],
cell signaling [27], hemostasis [20], tumor suppression [28],
inﬂammation [29] and complement activation [21]. Sushi
domainsareknownascomplementcontrolproteinmodules,
or short consensus repeats, found in complement and
adhesion proteins [30]. Sushi domain-containing proteins
operateinregulationofthecomplementsystemandinblood
clotting. Involvement of these proteins in cell adhesion [30],
embryogenesis [31] and blood coagulation [32] has also
been reported. In addition, the human SEZ6L and mouse
Sez6 genes, the homologous genes of Aig1l,h a v eb o t hC U B
and Sushi domains [11–13]. The Sez6 gene is reportedly
important for neuronal information transfer, which Gun-
nersen et al. [33] determined on the basis of analysis using
Sez6 knockout mice. Their report showed that Sez6 proteins
are important for normal dendritic arborization of cortical
neurons and for development of appropriate excitatory
synapticconnectivity.AllthesereportssuggestthatAig1lmay
be associated with neurotransmission and protein-protein
interaction. In view of the relation between those domains
of Aig1l and the eﬀect of EA, further analysis of Aig1l focused
on neurotransmission and protein-protein interaction may
reveal the functional importance of this gene.
In addition, we examined chronological changes in Aig1l
gene expression to verify the eﬀect of EA stimulation of
skeletal muscle on gene expression. We found that EA did
induce Aig1l gene expression, with the highest expression
measured after 3 hours of EA (Figure 3(c)). This result
suggests that the Aig1l gene is related to the rapid eﬀect of
EA stimulation.
During the process of Aig1l gene detection, we utilized
transcriptome and histochemical analyses and discovered
that EA induced a satellite cell-related proliferative reaction
in skeletal muscle [2]. Certain other research groups have6 Evidence-Based Complementary and Alternative Medicine
also reported transcriptome analysis of EA, which revealed
the eﬃcacy of EA stimulation: Kim et al. [5] showed that EA
increasednaturalkillercellactivitywithhigheﬃcacy,andKo
et al. [6], by using cDNA microarray analysis, reported that
theopioidreceptorwasinvolvedinanalgesicprocessesofEA.
Thus,transcriptomeanalysismaybeoneofthemosteﬀective
approaches for research in complementary and alternative
medicine.
In conclusion, we determined the full-length cDNA
sequence of the Aig1l gene and its expression in various
tissues (mainly brain). We showed chronological changes in
gene expression, with the greatest expression induced after 3
hours of EA. However, the biochemical function of the Aig1l
gene is not as yet fully explained. Additional investigations of
the Aig1l gene, including the relation between this gene and
EA, are warranted.
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